LISATA THERAP.INC.DL-001 (8NE) - Total Assets
Based on the latest financial reports, LISATA THERAP.INC.DL-001 (8NE) holds total assets worth €11.03 Million EUR (≈ $12.89 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LISATA THERAP.INC.DL-001 - Total Assets Trend (2021–2025)
This chart illustrates how LISATA THERAP.INC.DL-001's total assets have evolved over time, based on quarterly financial data. Also see LISATA THERAP.INC.DL-001 stock valuation for the company's overall valuation and market capitalisation.
LISATA THERAP.INC.DL-001 - Asset Composition Analysis
Current Asset Composition (December 2025)
LISATA THERAP.INC.DL-001's total assets of €11.03 Million consist of 99.8% current assets and 0.2% non-current assets. Review total liabilities of LISATA THERAP.INC.DL-001 to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 89.9% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how LISATA THERAP.INC.DL-001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 8NE live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LISATA THERAP.INC.DL-001's current assets represent 99.8% of total assets in 2025, an increase from 99.2% in 2021.
- Cash Position: Cash and equivalents constituted 89.9% of total assets in 2025, up from 25.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
LISATA THERAP.INC.DL-001 Competitors by Total Assets
Key competitors of LISATA THERAP.INC.DL-001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
LISATA THERAP.INC.DL-001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.69 | 5.77 | 8.03 |
| Quick Ratio | 3.69 | 5.77 | 8.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €8.03 Million | €20.57 Million | €33.00 Million |
LISATA THERAP.INC.DL-001 - Advanced Valuation Insights
This section examines the relationship between LISATA THERAP.INC.DL-001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -49.3% |
| Total Assets | €17.74 Million |
| Market Capitalization | $8.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values LISATA THERAP.INC.DL-001's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LISATA THERAP.INC.DL-001's assets decreased by 49.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LISATA THERAP.INC.DL-001 (2021–2025)
The table below shows the annual total assets of LISATA THERAP.INC.DL-001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €17.74 Million ≈ $20.74 Million |
-49.31% |
| 2024-12-31 | €35.00 Million ≈ $40.92 Million |
-36.00% |
| 2023-12-31 | €54.69 Million ≈ $63.94 Million |
-25.11% |
| 2022-12-31 | €73.03 Million ≈ $85.38 Million |
-24.71% |
| 2021-12-31 | €97.01 Million ≈ $113.41 Million |
-- |
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more